177 related articles for article (PubMed ID: 36799021)
21. [Genetic aspects of polycystic ovary syndrome].
Jakubowski L
Endokrynol Pol; 2005; 56(3):285-93. PubMed ID: 16350721
[TBL] [Abstract][Full Text] [Related]
22. Effects of electroacupuncture on the kisspeptin-gonadotropin-releasing hormone (GnRH) /luteinizing hormone (LH) neural circuit abnormalities and androgen receptor expression of kisspeptin/neurokinin B/dynorphin neurons in PCOS rats.
Xu G; Zhao X; Li Z; Hu J; Li X; Li J; Chen Y
J Ovarian Res; 2023 Jan; 16(1):15. PubMed ID: 36650561
[TBL] [Abstract][Full Text] [Related]
23. Accelerated subcutaneous abdominal stem cell adipogenesis predicts insulin sensitivity in normal-weight women with polycystic ovary syndrome.
Dumesic DA; Tulberg A; Leung KL; Fisch SC; Grogan TR; Abbott DH; Naik R; Chazenbalk GD
Fertil Steril; 2021 Jul; 116(1):232-242. PubMed ID: 33341231
[TBL] [Abstract][Full Text] [Related]
24. The AKR1C3/AR-V7 complex maintains CRPC tumour growth by repressing B4GALT1 expression.
Wang B; Wu S; Fang Y; Sun G; He D; Hsieh JT; Wang X; Zeng H; Wu K
J Cell Mol Med; 2020 Oct; 24(20):12032-12043. PubMed ID: 32902124
[TBL] [Abstract][Full Text] [Related]
25. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
[TBL] [Abstract][Full Text] [Related]
26. A Dietary Medium-Chain Fatty Acid, Decanoic Acid, Inhibits Recruitment of Nur77 to the HSD3B2 Promoter In Vitro and Reverses Endocrine and Metabolic Abnormalities in a Rat Model of Polycystic Ovary Syndrome.
Lee BH; Indran IR; Tan HM; Li Y; Zhang Z; Li J; Yong EL
Endocrinology; 2016 Jan; 157(1):382-94. PubMed ID: 26465200
[TBL] [Abstract][Full Text] [Related]
27. Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
García-Beltran C; Cereijo R; Quesada-López T; Malpique R; López-Bermejo A; de Zegher F; Ibáñez L; Villarroya F
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32107266
[TBL] [Abstract][Full Text] [Related]
28. Potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a bioisosteric scaffold hopping approach to flufenamic acid.
Pippione AC; Carnovale IM; Bonanni D; Sini M; Goyal P; Marini E; Pors K; Adinolfi S; Zonari D; Festuccia C; Wahlgren WY; Friemann R; Bagnati R; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2018 Apr; 150():930-945. PubMed ID: 29602039
[TBL] [Abstract][Full Text] [Related]
29. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer.
Hertzog JR; Zhang Z; Bignan G; Connolly PJ; Heindl JE; Janetopoulos CJ; Rupnow BA; McDevitt TM
Prostate; 2020 Oct; 80(14):1223-1232. PubMed ID: 33258507
[TBL] [Abstract][Full Text] [Related]
30. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
31. Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women.
Dumesic DA; Tulberg A; McNamara M; Grogan TR; Abbott DH; Naik R; Lu G; Chazenbalk GD
J Endocr Soc; 2021 Nov; 5(11):bvab158. PubMed ID: 34661039
[TBL] [Abstract][Full Text] [Related]
32. Androgen increases klotho expression via the androgen receptor-mediated pathway to induce GCs apoptosis.
Zeng X; Zhong Q; Li M; Liu Y; Long S; Xie Y; Mo Z
J Ovarian Res; 2023 Jan; 16(1):10. PubMed ID: 36641458
[TBL] [Abstract][Full Text] [Related]
33. Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.
Sanchez-Garrido MA; Tena-Sempere M
Mol Metab; 2020 May; 35():100937. PubMed ID: 32244180
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome.
Caldwell ASL; Edwards MC; Desai R; Jimenez M; Gilchrist RB; Handelsman DJ; Walters KA
Proc Natl Acad Sci U S A; 2017 Apr; 114(16):E3334-E3343. PubMed ID: 28320971
[TBL] [Abstract][Full Text] [Related]
35. Androgen excess and metabolic disorders in women with PCOS: beyond the body mass index.
Condorelli RA; Calogero AE; Di Mauro M; Mongioi' LM; Cannarella R; Rosta G; La Vignera S
J Endocrinol Invest; 2018 Apr; 41(4):383-388. PubMed ID: 28942551
[TBL] [Abstract][Full Text] [Related]
36. Androgen signaling pathways driving reproductive and metabolic phenotypes in a PCOS mouse model.
Aflatounian A; Edwards MC; Rodriguez Paris V; Bertoldo MJ; Desai R; Gilchrist RB; Ledger WL; Handelsman DJ; Walters KA
J Endocrinol; 2020 Jun; 245(3):381-395. PubMed ID: 32229702
[TBL] [Abstract][Full Text] [Related]
37. Serum metabolomics profiling by proton nuclear magnetic resonance spectrometry of the response to single oral macronutrient challenges in women with polycystic ovary syndrome (PCOS) compared with male and female controls.
Escobar-Morreale HF; Martínez-García MÁ; Insenser M; Cañellas N; Correig X; Luque-Ramírez M
Biol Sex Differ; 2023 Sep; 14(1):62. PubMed ID: 37736753
[TBL] [Abstract][Full Text] [Related]
38. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review.
Karunasinghe N; Masters J; Flanagan JU; Ferguson LR
Curr Cancer Drug Targets; 2017; 17(7):603-616. PubMed ID: 28359237
[TBL] [Abstract][Full Text] [Related]
39. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Goodman NF; Cobin RH; Futterweit W; Glueck JS; Legro RS; Carmina E; ; ;
Endocr Pract; 2015 Nov; 21(11):1291-300. PubMed ID: 26509855
[TBL] [Abstract][Full Text] [Related]
40. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
